KRAS and neoplasm: We evaluated 89Zr-cetuximab PET imaging in patients with wt K-RAS mCRC and found tumor uptake of 89Zr-cetuximab in 6 out of 10 patients of whom 4 had clinical benefit of cetuximab treatment (Table 1).